EADV 2025: Advancing Treatment Frontiers in Hidradenitis Suppurativa

At the EADV 2025 Congress, Thrasyvoulos Tzellos, MD, PhD, Head Physician at the Department of Dermatology, Nordland Hospital Trust in Bodø, Norway, presented promising new directions in the treatment of hidradenitis suppurativa. He highlighted emerging biologics targeting IL-17 and IL-1 pathways, JAK inhibitors, and combination therapies aimed at both inflammation and fibrosis. With several agents in late-stage trials, the future of HS treatment was shown to be increasingly targeted and effective.